Emil Kuriakose - Mar 10, 2024 Form 3 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Chief Medical Officer
Signature
/s/ Bryan Yoon, as Attorney-in-Fact for Emil Kuriakose
Stock symbol
TERN
Transactions as of
Mar 10, 2024
Transactions value $
$0
Form type
3
Date filed
3/19/2024, 07:26 PM
Previous filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TERN Common Stock 58.8K Mar 10, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TERN Stock Option (Right to buy) Mar 10, 2024 Common Stock 280K $12.93 Direct F2
holding TERN Stock Option (Right to buy) Mar 10, 2024 Common Stock 118K $5.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2 25% of the shares subject to the option vest on the first anniversary measured from May 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F3 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24.1 - Power of Attorney